Chlorpheniramin 4mg
Indications
– Seasonal and perennial allergic rhinitis. – Other allergic symptoms such as: + Urticaria, conjunctivitis, contact dermatitis, angioedema, Quincke’s disease, food allergy, serum disease. + Insect bites. + Pruritus skin caused by
Present
Blister of 20 tablets. Box of 5 blister.
Composition
Chlorpheniramine maleat e 4mg Excipients s.q. for 1 tablet (Lactose, Cassava starch, Corn starch, Talc, Quinoline yellow, Magnesium stearate).
Actions
Chlorpheniramine maleate, an alkylamine derivative, is a sedating antihistamine. It is an H1– receptor antagonist that causes a moderate degree of sedation.
Contra-Indications
– Hypersensitivity to any ingredient of the medicine. – Patients in acute asthmatic attack. – Narrow angle glaucoma, prostate hypertrophy. – Bladder neck obstruction. – Stenosing peptic ulcer, pyloroduodenal obstruction. – Neonates and prematures. – Patients that are taking monoamine oxidase inhibitor (MAOI), or within 2 weeks after stopping MAOI drugs.
Side effect
– Drowsiness, sedation, dryness of mouth, dizziness, nausea. Inform your doctor about side– effects when using this medicine.
Precaution
– Use with caution in patients with chronic pulmonary disorders, breath shortness and difficulty. – Use with caution in elderly patients (older than 60 years of age) due to the increased sensitivity to anticholinergic activity in these patients. – The drug may cause drowsiness, dizziness, therefor use with caution in drivers or operators of machinery.
Interaction
– MAOI drugs prolong and intensify the anticholinergic activity of antihistamine drugs. – Alcohol, alcoholic beverages and other sedative drugs may potentiate the sedative effect of Chlorpheniramine. – Chlorpheniramine inhibits Phenytoine metabolism and may lead to Phenytoine intoxication.
Shelf life
36 months from the manufacturing date.
Storage
Store in a dry place, not exceeding 30oC. Protect from light.
Dosage
– Children: 1/2 – 1 tablet x 2 times daily. – Adults: 1 tablet x 3 times daily.
Reviews
There are no reviews yet.